Iovance Biotherapeutics
IOVA
IOVA
131 hedge funds and large institutions have $1.02B invested in Iovance Biotherapeutics in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 48 increasing their positions, 30 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
1.8% more ownership
Funds ownership: 92.86% → 94.66% (+1.8%)
4% less capital invested
Capital invested by funds: $1.07B → $1.02B (-$47.5M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Holders
131
Holding in Top 10
7
Calls
$5M
Puts
$1.48M
Top Buyers
| 1 | +$32M | |
| 2 | +$16.2M | |
| 3 | +$15M | |
| 4 |
BC
Broadfin Capital
New York
|
+$8.41M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$5.96M |
Top Sellers
| 1 | -$20.3M | |
| 2 | -$7.34M | |
| 3 | -$4.61M | |
| 4 |
6CM
683 Capital Management
New York
|
-$4.48M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.16M |